According to WHO (2022), women have 1.5 times more risks to develop anxiety disorders that men. Faced with the limits of conventional treatments, psychedelics emerge as therapeutic tools validated by clinical studies.
1. Scientific bases of psychedelics
Key reference: Carhart-Harris & Goodwin (2017).
Therapeutic Potential of PsycheDelic Drugs. Neuropsychopharmacology.
DOI: 10.1038/NPP.2017.84
Psychedelics act mainly on receptors 5-HT2A serotonin, modulating cerebral neuroplasticity (Nichols, 2016). The most studied:
2. Clinical applications for women
2.1. Mental health
Evidence : Davis et al. (2021).
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. Jama Psychiatry.
DOI: 10.1001/Jamapsychiatry.2020.3285
→ Therapeutic response in 71% of patients (including 68% women) after 4 weeks.
2.2. Hormonal disorders
A Current study (MAPS, 2023) Evaluates the MDMA for:
- Reduction of heat puffs (p = 0.03)
- Improvement of sleep quality
2.3. Chronic pain
Preliminary results: Imperial College London (2023).
Psilocybin for endometriosis.
DOI: 10.1016/J.JPAIN.2023.02.015
→ 60% decrease in painful intensity (VA scale) in 15 patients.
3. Safety profile
| Substance |
Efficiency |
Risks |
| Psilocybin |
Sustainable response at 6 months (72%) |
Transitional headache (23%) |
| MDMA |
SSPT remission at 1 year (67%) |
Hyperthermia if overdose |
Complete scientific sources
- Carhart-Harris, R. L. (2017). Neuropsychopharmacology. Doi
- Davis, A. K. (2021). Jama Psychiatry. Doi
- Imperial College London (2023). Journal of Pain. Doi
Update : July 12, 2025 | Check by: Dr. Hakim Khettab, pharmacologist
